On this page:
Find past issues on the newsletter search page.
Q: Why does a recent guideline recommend against the use of DPP4 inhibitors such as linagliptin (Trajenta®) in people with type 2 diabetes?
A: The answer is in the current edition of PAD Refills. Make sure to subscribe so you don’t miss out on news and updates!
Effective June 11, 2024, US-labelled carbamazepine extended-release 200 mg and 400 mg tablets were temporarily added as PharmaCare regular benefits.
Health Canada has permitted the exceptional, temporary sale of US-labelled carbamazepine extended-release tablets, imported by Septa Pharmaceuticals Inc., during the shortage of Canadian-marketed carbamazepine controlled release tablets.
The US products have the same active ingredient, strengths, dosage form (expressed as “extended release” tablets rather than “controlled release”) and route of administration as the Canadian products. However, the US products have a different formulation, and their bioequivalence to the Canadian products has not been confirmed.
Carbamazepine has a narrow therapeutic index. Interchanging between non-bioequivalent products with a narrow therapeutic index may result in patients receiving minor variations in drug concentration, which may affect the effectiveness and/or safety of the drug.
US products also differ from the Canadian-market versions in their labelling (English-only), physical appearance, and non-medicinal ingredients.
To dispense US-labelled carbamazepine extended-release tablets
Some product may be available from select distributors in B.C. Direct order is available from Septa Pharmaceuticals Inc.
Resources
On July 15, 2024, BC PharmaCare will delist the alpha-1 proteinase inhibitor Prolastin-C, as Canadian Blood Services (CBS) has added the alpha-1 proteinase inhibitor Glassia to its formulary.
Prolastin-C will no longer be covered for new patients. Existing Prolastin-C patients will have PharmaCare coverage for up to 6 months, to January 14, 2025, to allow time to meet with their prescribers and transition to Glassia.
Glassia is not dispensed through community pharmacies. CBS coordinates patient pick-up at transfusion medicine laboratories.
PharmaCare has asked prescribers to transition their existing Prolastin-C patients to Glassia as soon as possible. Pharmacists are encouraged to advise Prolastin-C patients to meet with their prescribers.
To manage Prolastin-C supply over the coming months, pharmacies should be aware that:
Transition timeline | ||
---|---|---|
July 15, 2024 | July 15, 2024, to January 14, 2025 | January 15, 2025 |
PharmaCare stops covering Prolastin-C for new patients. Existing patients get transitional coverage for up to 6 months. |
New patients are prescribed Glassia only, available through CBS. Pharmacists encourage existing Prolastin-C patients to meet with prescribers to transition to Glassia. |
Prolastin-C is no longer covered for B.C. patients. |
Resources
Effective August 30, 2024, pharmacists will be recognized as referring practitioners in the Laboratory Services Regulation under the Laboratory Services Act, a change that will allow them to order certain laboratory tests for medication management. The regulation change will equip pharmacists with additional clinical tools to provide medication management services.
The plan for enabling and onboarding pharmacists will be communicated soon. Implementation will start in some hospital inpatient settings on August 30, with expansion to community settings in the following months.
The College of Pharmacists of BC (CPBC) is creating standards, limits and conditions for ordering, receiving and interpreting laboratory tests. They will communicate these to registrants.
The pharmacist laboratory services referring schedule is viewable in Ministerial Order (M198-2024).
Pharmacists will be required to complete a free hour-long training module before they can acquire a Practitioner ID, which will be needed to order laboratory tests.
This mandatory training will be offered through UBC Continuing Pharmacy Professional Development (CPPD), along with optional accredited clinical education on interpreting laboratory results.
Please note that no specific fees will be available for ordering laboratory tests. The new authority is intended to enhance pharmacists’ ability to perform comprehensive patient assessments for drug therapy management. Pharmacists may continue to submit claims for clinical services fees or medication reviews in accordance with the PharmaCare Policy Manual.
Be sure you are subscribed to the PharmaCare Newsletter so you do not miss updates on this exciting announcement, and visit the new webpage Pharmacists referring lab tests, which will also be a key resource as this initiative progresses.
For any questions about pharmacist lab ordering, please email PCI@gov.bc.ca
Resources
The Ministry of Health, the College of Pharmacists of BC and the BC Pharmacy Association are jointly hosting a webinar for B.C. pharmacists about their various initiatives that will enhance pharmacy practice in B.C., including:
The event will be held online on Thursday, July 25, from 6 pm to 8 pm. Registration and attendance is free for all pharmacists.
Please note that BCPhA is supporting registration for the event. BCPhA membership is NOT required. However, a BCPhA account is necessary, and can be created by any pharmacist with valid College registration.
When pharmacy staff leave employment, the pharmacy must make sure that no unauthorized access to PharmaNet by the former employee occurs or appears to occur at their pharmacy.
The pharmacy will need to:
If the pharmacy upgrades a system or restores information from backup files, they should make sure the former employee’s credentials have not been reactivated.
Pharmacies are responsible for ensuring no unauthorized access to PharmaNet occurs at their pharmacy. Read more at Pharmacy access to PharmaNet.
Resources
As part of ongoing efforts to provide easy-to-understand resources for B.C. residents and health professionals, the PharmaCare communications team has updated the PharmaCare patient information sheets.
Each information sheet is now available in 15 languages: Arabic, Chinese Simplified and Traditional, English, Filipino (Tagalog), French, Hindi, Japanese, Korean, Persian, Punjabi, Russian, Spanish, Ukrainian and Vietnamese.
Pharmacists and pharmacy staff are encouraged to:
The sheets are also a great resource for new staff to learn about PharmaCare and explain the public program to clients.
As part of the updates, the six Fair PharmaCare-related info sheets have been consolidated into one, allowing for a single, straightforward, and accessible resource for all clients. Additionally, a new information sheet explains pharmacy services in B.C., including prescription adaptations, the minor ailment and contraception service (MACS), and drug administrations.
The info sheets are now:
Is there a topic we’re missing? What information sheet would help you support your clients? Send ideas to: PharmaCareInfo@gov.bc.ca
The Therapeutics Initiative (TI) collaborated with the BC Centre for Disease Control (BCCDC) to provide dentists with evidence-based advice to treat infections in patients who report penicillin allergies.
Dentists are advised that clindamycin should not be used routinely for prophylaxis or management of dental infections because it is more strongly associated with the development of C. difficile colitis compared to other antibiotics, and that cefuroxime is a safe option for most patients, even if they have a true penicillin allergy. Cross-reactivity depends on the similarity of side chain structures, and cefuroxime’s side chain does not resemble that of amoxicillin or penicillin.
Visit TI: Cefuroxime is a safe alternative for penicillin allergic patients to read the letter.
Resources
How do pharmacists feel about prescribing for contraception?
Researchers from UBC’s Faculty of Pharmaceutical Sciences and the Contraception and Abortion Research Team (CART) are conducting a study to understand pharmacist perspectives and experiences of prescribing for contraception, and the factors that facilitate and limit their providing the service.
Visit ACT-Pharm III survey to learn more and to participate in a survey.
The survey will be available until August 30, 2024, at 11:59 pm. Participation is voluntary. Participants receive a $20 e-transfer as a token of appreciation.
The study’s principal investigator is Dr. Laura Schummers, an assistant professor of health outcomes in the Faculty of Pharmaceutical Sciences. If you have any questions or encounter issues with the survey, please contact pharmcontraception.survey@ubc.ca.
Resources
Since the last newsletter, PharmaCare has paid pharmacies for COVID-19 rapid antigen test (RAT) kit distribution as follows:
Payment month | Payment date |
---|---|
April 2024 | July 2, 2024 |
Pharmacies are paid $75 for each case of RAT kits distributed, and pharmacists are reminded to enter the correct PIN for each case of RAT kits distributed.
Resources
Prescribers and pharmacists are submitting Special Authority requests online through eForms and leaving the slower ways behind — reducing approval wait times for their patients. Get on board! Visit Special Authority eForms to learn about eForms and sign up.
Resources
PharmaCare has added the following regular benefit coverage items to the PharmaCare drug list.
Drug name | budesonide rectal foam (Uceris™) | ||
---|---|---|---|
Date effective | June 18, 2024 | ||
Indication |
For the induction of remission in adult patients with active mild to moderate distal ulcerative colitis. |
||
DINs | 02498057 | Strength & form | 2 mg/actuation |
Special notes | When submitting to PharmaCare, please bill per actuation. |
PharmaCare has added the following Limited Coverage items to the PharmaCare drug list. Special Authority approval is required for coverage.
Drug name | etanercept biosimilar (Rymti®) | ||
---|---|---|---|
Date effective | June 25, 2024 | ||
Indication |
|
||
DINs |
02530295 |
Strength & form |
50 mg/mL solution for injection in prefilled syringe |
Drug name | adalimumab biosimilars (Abrilada™, Amgevita®, Hadlima®, Hulio®, Hyrimoz®, Idacio®, Simlandi™, Yuflyma®) | ||
---|---|---|---|
Date effective | July 3, 2024 | ||
Indication | For the treatment of active non-infectious uveitis for patients 2 years and older. | ||
DINs | Multiple DINs | Strength & form | Multiple dose strengths and forms |
Drug name | adalimumab biosimilars (Abrilada®) | ||
---|---|---|---|
Date effective | July 3, 2024 | ||
Indication | For the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, moderate to severe plaque psoriasis, moderate to severe active polyarticular juvenile idiopathic arthritis for patients 2 years and older, adult patients with active moderate to severe hidradenitis suppurativa, moderate to severe active Crohn's disease or fistulizing Crohn's disease, moderate to severe ulcerative colitis, and active non-infectious uveitis for patients 2 years and older. | ||
DINs | 02511061 | Strength & form | 20 mg/0.4 mL pre-filled syringe |
Drug name | adalimumab biosimilar (Hyrimoz®) | ||
---|---|---|---|
Date effective | July 3, 2024 | ||
Indication | For the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, moderate to severe plaque psoriasis, moderate to severe active polyarticular juvenile idiopathic arthritis for patients 2 years and older, adult patients with active moderate to severe hidradenitis suppurativa, moderate to severe active Crohn's disease or fistulizing Crohn's disease, moderate to severe ulcerative colitis, and active non-infectious uveitis for patients 2 years and older. | ||
DINs | 02542358 02542366 02542323 02542331 02542315 |
Strength & form | 80 mg/0.8 mL pre-filled syringe 80 mg/0.8 mL autoinjector pen 40 mg/0.4 mL pre-filled syringe 40 mg/0.4 mL autoinjector pen 20 mg/0.2 mL pre-filled syringe |
Amgen Canada Inc. is discontinuing 120 mg/mL (420 mg/3.5 mL) automated mini-doser (Repatha® AMD) in all countries, including Canada. Evolocumab remains available in 140 mg/mL SureClick® autoinjector form (DIN: 02446057).
Drug name | evolocumab injection (Repatha®) | ||
---|---|---|---|
Date effective | The inventory is anticipated to be depleted in July 2024. | ||
Indication | For the treatment of heterozygous familial hypercholesterolemia (HeFH) as an adjunct to maximally tolerated HMG-CoA reductase inhibitors (statins) therapy in adult patients who are unable to reach target low density lipoprotein cholesterol (LDL-C) levels. | ||
DINs | 02459779 | Strength & form | 120 mg/mL (420 mg in 3.5mL AMD with prefilled cartridge) |
Health professionals are encouraged to transition patients to the still available 140 mg/mL SureClick® autoinjector, with a dose frequency of every two weeks.
On March 1, 2024, prednisolone sodium phosphate (Pediapred®) 5 mg/5 mL, oral liquid 120 mL bottle, was discontinued, with the last lot expiring on July 31, 2024.
Drug name | prednisolone sodium phosphate (Pediapred®) | ||
---|---|---|---|
Date effective | August 1, 2024 | ||
Indication | Corticosteroids, systemic. | ||
DINs | 02230619 | Strength & form | 5 mg/5 mL, oral liquid 120 mL bottle |
PharmaCare will be delisting Pediapred on August 1, 2024; however, pms-prednisolone (prednisolone sodium phosphate) 5 mg/5 mL oral solution remains a regular benefit under the PharmaCare formulary and will remain available.
Effective August 2, 2024, PharmaCare will change the correct quantities policy for the filgrastim biosimilars – Grastofil and Nypozi. To ensure the efficient and accurate adjudication of claims in PharmaNet, pharmacies must now enter claims for Grastofil and Nypozi using number of prefilled syringes. There are no changes to the correct quantities policy for filgrastrim (Nivestym®) and pharmacies can continue to enter claims for Nivestym using number of syringes or vials.
Drug | Dosage | DINs | Old Correct Quantities policy | New Correct Quantities policy |
---|---|---|---|---|
Filgastrim biosimilar (Grastofil) | 300 mcg/0.5 mL syringe | 02441489 | Volume in millilitres | Number of prefilled syringes |
Filgastrim biosimilar (Grastofil) | 480 mcg/0.8 mL syringe | 02521008 | Volume in millilitres | Number of prefilled syringes |
Drug | Dosage | DINs | Old Correct Quantities policy | New Correct Quantities policy |
---|---|---|---|---|
Filgastrim biosimilar (Nypozi) | 300 mcg/0.5 mL syringe | 02520990 | Volume in millilitres | Number of prefilled syringes |
Filgastrim biosimilar (Nypozi) | 480 mcg/0.8 mL syringe | 02521008 | Volume in millilitres | Number of prefilled syringes |
Effective August 2, 2024, the prices for the following products will be reduced.
Prices include 8% markup-up.
Drug name | filgrastim (Nivestym®) | Strength and form | Current price per syringe ($) |
Reduced price per syringe ($) |
|
---|---|---|---|---|---|
Date effective | August 2, 2024 | ||||
DINs | 02485575 | 300 mcg/0.5 mL syringe | 155.8548 | 149.6206 | |
02485583 | 480 mcg/0.8 mL syringe | 249.3720 | 239.3971 | ||
02485591 | 300 mcg/1 mL vial | 155.8548 | 149.6206 | ||
02485656 | 480 mcg/1.6 mL vial | 249.3720 | 239.3971 |
Drug name | filgrastim (Grastofil®) | Strength and form | Current price per syringe ($) |
Reduced price per syringe ($) |
|
---|---|---|---|---|---|
Date effective | August 2, 2024 | ||||
DINs | 02441489 | 300 mcg/0.5 mL syringe | 155.8548 | 149.6210 | |
02454548 | 480 mcg/0.8 mL syringe | 249.3720 | 239.3928 |
The knowledge and experience of patients, caregivers and patient groups is integral to B.C.’s drug review process. If you know someone who’s taking one of the drugs below or who has a condition any of the drugs treats, please encourage them to visit www.gov.bc.ca/BCyourvoice.
Your Voice is now accepting input on the following drugs:
Drug | Indication | Input window |
---|---|---|
elexacaftor-tezacaftor-ivacaftor and ivacaftor (Trikafta®) | For the treatment of cystic fibrosis (CF) in children ages 2+. | June 26 to July 23 at 11:59 pm |
baricitinib (Olumiant®) | For the treatment of severe alopecia areata (AA) in adults. | June 26 to July 23 at 11:59 pm |
PharmaCare newsletters are published on the first Tuesday of each month, with special releases sometimes published mid-month. Newsletters communicate drug listings, PharmaCare and PharmaNet policy updates, and other pertinent information for PharmaCare providers and other B.C. health professionals.
Enter your email address to subscribe to updates of this page.
The PharmaCare Newsletter team works from the territory of the Lekwungen People, including the Songhees and Esquimalt Nations. Our gratitude extends to them, and all the Indigenous Peoples on whose territories and lands we build relationships.
Search past newsletters on the Newsletter search page.
BC PharmaCare counts on pharmacy and device providers to practise cultural safety and humility.
To learn more, read Coming Together for Wellness, a series of articles by First Nations Health Authority (FNHA) and PharmaCare, and consider taking the online San’yas Indigenous Cultural Safety course.
Active advisories:
Dextroamphetamine SR capsules; Cholestyramine, colestipol and colesevelam; Tamsulosin capsules and tablets; Prazosin tablets, Sabril® tablets; nitroglycerin sprays & tablets; pediatric antibiotic suspensions; Glucagon for injection.
Visit Drug shortages for full list and details.